Assignee
ASTEX THERAPEUTICS LTD
GB·67 granted patents·49 pending applications·651 citations·filing 2003–2024
Top patents by PatentIndex Score
116 records- 0196US7754725B2Dihydroxyphenyl isoindolymethanonesASTEX THERAPEUTICS LTD·Filed 2007·Granted Jul 13, 2010·22 cites·10 claims
- 0295US10544132B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 28, 2020·10 cites·27 claims
- 0395US9850228B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Dec 26, 2017·17 cites·5 claims
- 0495US9464071B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2014·Granted Oct 11, 2016·24 cites·45 claims
- 0595US9458158B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2015·Granted Oct 4, 2016·11 cites·22 claims
- 0695US9447098B2Pteridines as FGFR inhibitorsASTEX THERAPEUTICS LTD·Filed 2013·Granted Sep 20, 2016·35 cites·20 claims
- 0795US7385059B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2006·Granted Jun 10, 2008·33 cites·20 claims
- 0894US9309242B2Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 12, 2016·26 cites·28 claims
- 0994US9303029B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 5, 2016·25 cites·20 claims
- 1094US9303030B2CompoundsASTEX THERAPEUTICS LTD·Filed 2013·Granted Apr 5, 2016·26 cites·21 claims
- 1194US7700625B2Hydroxybenzamide derivatives and their use as inhibitors of Hsp90ASTEX THERAPEUTICS LTD·Filed 2007·Granted Apr 20, 2010·25 cites·10 claims
- 1293US11225476B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2020·Granted Jan 18, 2022·3 cites·13 claims
- 1393US9856236B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2015·Granted Jan 2, 2018·16 cites·20 claims
- 1493US9737544B2CompoundsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 22, 2017·15 cites·20 claims
- 1593US9439896B2Quinolines as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Sep 13, 2016·22 cites·20 claims
- 1692US11866428B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2020·Granted Jan 9, 2024·2 cites·21 claims
- 1792US10981898B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Apr 20, 2021·4 cites·27 claims
- 1892US10526311B2Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 7, 2020·6 cites·25 claims
- 1992US10052320B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 21, 2018·11 cites·20 claims
- 2092US10045982B2Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 14, 2018·11 cites·33 claims
- 2192US10039759B2Quinolines as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 7, 2018·11 cites·21 claims
- 2292US9617248B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2013·Granted Apr 11, 2017·10 cites·20 claims
- 2392US9527844B2Naphthyridine derivative compoundsASTEX THERAPEUTICS LTD·Filed 2015·Granted Dec 27, 2016·20 cites·16 claims
- 2492US9493426B2Quinazolinone derivatives useful as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2014·Granted Nov 15, 2016·20 cites·20 claims
- 2591US9980973B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Granted May 29, 2018·6 cites·21 claims
- 2691US9902714B2Quinoxaline derivatives useful as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2015·Granted Feb 27, 2018·15 cites·22 claims
- 2791US9783538B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2014·Granted Oct 10, 2017·12 cites·53 claims
- 2891US9757364B2Naphthyridine derivative compoundsASTEX THERAPEUTICS LTD·Filed 2016·Granted Sep 12, 2017·15 cites·21 claims
- 2991US9309241B2Naphthyridine derivative compoundsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 12, 2016·26 cites·17 claims
- 3090US11643410B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2021·Granted May 9, 2023·1 cites·22 claims
- 3190US10519137B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2017·Granted Dec 31, 2019·6 cites·18 claims
- 3290US10085982B2CombinationsASTEX THERAPEUTICS LTD·Filed 2015·Granted Oct 2, 2018·12 cites·12 claims
- 3390US9676768B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2015·Granted Jun 13, 2017·8 cites·16 claims
- 3490US7977477B2Benzimidazole derivatives and their use as protein kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2004·Granted Jul 12, 2011·35 cites·23 claims
- 3589US10898482B2Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamineASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 26, 2021·7 cites·66 claims
- 3689US2025296930A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 3788US10716787B2CombinationsASTEX THERAPEUTICS LTD·Filed 2018·Granted Jul 21, 2020·3 cites·13 claims
- 3888US7825140B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2007·Granted Nov 2, 2010·7 cites·19 claims
- 3988US7745638B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2007·Granted Jun 29, 2010·8 cites·23 claims
- 4087US10736900B2Combinations of an FGFR inhibitor and an IGF1R inhibitorASTEX THERAPEUTICS LTD·Filed 2015·Granted Aug 11, 2020·4 cites·7 claims
- 4187US10618895B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Granted Apr 14, 2020·4 cites·33 claims
- 4287US10421747B2Quinoxaline derivatives useful as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2017·Granted Sep 24, 2019·6 cites·19 claims
- 4386US9617283B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2013·Granted Apr 11, 2017·10 cites·20 claims
- 4486US8383619B2Pharmaceutical compoundsASTEX THERAPEUTICS LTD·Filed 2010·Granted Feb 26, 2013·8 cites·13 claims
- 4585US11261171B1Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Mar 1, 2022·2 cites·24 claims
- 4685US10272087B2Pteridines as FGFR inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Apr 30, 2019·5 cites·21 claims
- 4785US2024199607A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 4884US12202828B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2022·Granted Jan 21, 2025·0 cites·48 claims
- 4984US12077526B2Isoindolinone inhibitors of the MDM2-P53 interaction and process for making themASTEX THERAPEUTICS LTD·Filed 2023·Granted Sep 3, 2024·1 cites·22 claims
- 5084US11236047B2Combination of isoindolinone derivatives with SGI-110ASTEX THERAPEUTICS LTD·Filed 2018·Granted Feb 1, 2022·2 cites·21 claims
Showing the top 50 of 116 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →